Helping organizations align with these trends is Artialis Group—a CRO specialized in the development of therapies and biomarkers in the field of musculoskeletal disorders, including osteoarthritis, sarcopenia, tendinopathies, and intervertebral disk degeneration. “We laid the foundation of Artialis to meet the quality criteria and regulatory requirements of the pharmaceutical and food industry in the development of new treatments for musculoskeletal diseases,” says Professor Yves Henrotin, President and CEO of Artialis. “Artialis is unique because it is the only CRO in this field that offers a complete “all-in one” solution allowing customers to have only one partner for the different development phases of their product—from preclinical to post marketing clinical trials.” Indeed, the company has developed original cellular and animal models allowing not only the screening but also the study of the mechanisms of action of a molecule. It is also highly specialized in the identification and development of biochemical markers used as “drug development tools” or as companion biomarkers in the monitoring of treatment efficacy.
Artialis Group : One Partner from Drug Discovery to Marketing
Artialis is unique because it is the only CRO in this field that offers a complete “all-in one” solution allowing customers to have only one partner for the different development phases of their product—from preclinical to post marketing clinical trials
Further, Artialis has acquired many skills in OMICS technologies. Through its collaboration with a technological platform, Artialis performs transcriptomic, metabolomic, and proteomic analyses of various biological fluids. This approach helps identify mechanisms of action for innovative treatments. Every study design is customised to address the clients’ requirements based on the test product.
Having such a comprehensive offering, Artialis has become the preferred provider for Nestlé. Artialis contributes to Nestlé’ products from cells screening to clinical trial. It was also a partner of the veteran affair of the US Army for testing biomarkers in large cohorts. Moreover, Artialis is involved in two international and transversal projects, IMI APPROACH and DEMAIN, to identify novel biomarkers for osteoarthritis and sarcopenia, respectively. “We always strive to integrate new and innovative biomarkers into our portfolio so that clients can take advantage of state-of-the-art biomarker testing capacities,” says Professor Henrotin. As a provider of “all-in-one solution,” Artialis is the best drug development partner in the field of MSK disorders due to its reputation, experience, scientific competence, and wide range of technological solutions.
